Location History:
- Suita, JP (2013)
- Osaka, JP (2019 - 2020)
Company Filing History:
Years Active: 2013-2025
Title: Hiroto Tatamidani: Innovator in Pharmaceutical Chemistry
Introduction
Hiroto Tatamidani is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 5 patents. His innovative methods have advanced the production of various chemical compounds, showcasing his expertise and dedication to research.
Latest Patents
Tatamidani's latest patents include a method for producing cis-(-)-flocino piperidol. This invention provides a process that utilizes (+)-dibenzoyl-D-tartaric acid to optically divide (±)-1-methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinone. By adding an ether-based solvent, an extremely high yield of (R)-1-methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinone (+)-dibenzoyl-D-tartrate is achieved. The method further involves treating a slurry with a base and using a 'three-dimensionally bulky reducing agent' to produce cis-(−)-flocinopiperidol with remarkable selectivity. Another notable patent is a method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione. This invention addresses the need for an industrially viable production method by reacting 3-bromo-3-buten-2-one and 2-hydroxy-1,4-naphthoquinone in the presence of a solvent. The process culminates in obtaining crystals of 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione through the addition of an alcohol-based solvent and/or water.
Career Highlights
Throughout his career, Hiroto Tatamidani has worked with notable companies such as Sumitomo Dainippon Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in pharmaceutical research.
Collaborations
Tatamidani has collaborated with esteemed colleagues, including Toshikazu Yagi and Satoshi Suzuki. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion